A gene therapy biotech is bursting onto the scene with 12 programs in tow. An ultra-rare neuro disease is up first

Nicole DeFeudis

Editor

In downtown Lowell, MA, tucked into one of the country’s oldest surviving textile mill complexes is a new biotech toiling away on next-gen CNS therapies …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

A gene therapy biotech is bursting onto the scene with 12 programs in tow. An ultra-rare neuro disease is up first

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

A gene ther­a­py biotech is burst­ing on­to the scene with 12 pro­grams in tow. An ul­tra-rare neu­ro dis­ease is up first

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

A gene therapy biotech is bursting onto the scene with 12 programs in tow. An ultra-rare neuro disease is up first